Cardiovascular Risk Panel

A comprehensive nine-biomarker assessment of cardiovascular risk, covering the full lipid spectrum together with key inflammatory and vascular markers. At PKBH's Olomouc central laboratory, biochemistry assays run on the Mindray BS-800 M2 analyser, Apolipoprotein A1 and B are quantified by immunoturbidimetry, and Lipoprotein(a) is measured alongside Homocysteine — markers that standard NHS-style cholesterol checks omit entirely. The combined picture distinguishes true low-density atherogenic particles from HDL-protected cholesterol and flags elevated inflammatory tone driven by CRP. Walk-in access, no referral required, results by end of day or next morning.

Cardiovascular disease remains the leading cause of premature death across Europe, and most risk is invisible until an event occurs. This nine-biomarker panel is designed to close that gap by profiling every major modifiable driver of arterial disease in a single morning blood draw at any PKBH Olomouc collection site. The panel covers: total cholesterol, HDL cholesterol, LDL cholesterol, triglycerides, Apolipoprotein A1, Apolipoprotein B, Lipoprotein(a) (Lp(a)), Homocysteine, and high-sensitivity C-reactive protein (CRP). Why this combination matters: - **Cholesterol + LDL + HDL + triglycerides** form the baseline lipid picture required by every cardiovascular risk calculator (SCORE2, Framingham). - **Apolipoprotein B** directly counts the number of atherogenic lipoprotein particles and is a more accurate predictor of cardiovascular events than LDL-cholesterol alone in people with metabolic syndrome or diabetes. - **Apolipoprotein A1** reflects HDL particle functionality, not just concentration. - **Lipoprotein(a)** is genetically determined and elevates risk independently of LDL — it is measured here on the Mindray BS-800 M2 at a transparent self-pay price of 69 Kč, making it one of the most affordable Lp(a) assays in the Czech Republic. - **Homocysteine** is a modifiable vascular endothelial toxin associated with a doubled cardiovascular event risk when chronically elevated; dietary B-vitamin supplementation can normalise it. - **CRP** quantifies systemic low-grade inflammation, the biological mechanism linking metabolic disease to arterial damage. At PKBH, all biochemistry markers run on the automated Mindray BS-800 M2 line, which performs high-throughput analysis with internal QC checks each run. Immunochemistry-based markers (Apolipoproteins) use the Abbott Alinity ii or DPC Immulite 2000XPi platform, accredited under the SEKK external quality programme. The laboratory holds R3 Audit certification for biochemistry — the highest tier in the Czech healthcare quality system. **Who benefits:** Anyone with a family history of heart attack or stroke before age 60, people with type 2 diabetes or metabolic syndrome, adults on statin therapy wanting to verify treatment adequacy, individuals with obesity or central adiposity, and anyone over 40 who has never had a full lipid screen. **Preparation:** Fast for 10–12 hours before the draw (water and medication as normal). Arrive at any PKBH Olomouc site from 07:00, no appointment required. The blood draw takes under five minutes. **Results:** Printed and electronic results are issued on the same working day or the next morning. If a result exceeds a critical threshold, PKBH phones the patient directly within two hours of analysis (STATIM protocol). No doctor's referral is required for self-pay testing — bring a photo ID and the published fee in cash.